According to the results of the interim assessment of the third phase of clinical trials of the Sputnik V vaccine, the effectiveness of the drug was 92%, the developers say. No serious adverse events were found in the vaccinated.
Center specialists. The Gamalei conducted the first interim analysis of the third phase of clinical trials and evaluated the effectiveness of the vaccine based on the results of observations of 16,000 volunteers 21 days after the second injection. The statistical analysis included 20 confirmed cases identified in the vaccine and placebo groups. Experts estimated the effectiveness of the Sputnik V vaccine at 92%, reports Russian Direct Investment Fund (RDIF).
An assessment was also made of observations of 10,000 medical personnel who received the vaccine outside of clinical trials. In this group, the effectiveness of the drug was 90%. None of the groups showed any unexpected side effects. Some of the vaccinated had pain at the injection site, fever, weakness, but all these conditions were short-term. The RDIF report indicates that the team of the Gamaleya Center plans to publish the obtained data in one of the leading peer-reviewed medical publications.
On November 9, the American pharmaceutical company Pfizer and its German biotechnological partner BioNTech announced similar results of the III phase of clinical trials of a vaccine against coronavirus. The short report states that the BNT162b2 coronavirus drug has shown an efficacy of more than 90% in clinical trials involving volunteers. Pfizer intends to ask the Food and Drug Administration (FDA) to authorize the vaccine for emergency use.
Earlier, the World Health Organization said that it would consider the COVID-19 vaccine effective only if it works 50% of the time for several months.